The Zhitong Finance App learned that according to the latest data from the Hong Kong Stock Exchange, on July 31, Weilizhibo-B (09887) had a position change, with a total transfer market value of HK$364 million, accounting for 3.62%. The company's shareholders transferred 3.126,400 shares to Citibank and 4,0694 million shares were transferred from China Securities Registration and Settlement Hong Kong.

Verishibo-B announced that the China National Drug Administration (China Drug Administration) Drug Evaluation Center (CDE) has approved a new drug clinical trial application (IND) for its self-developed drug candidate Vilisin™ (PD-L1/4-1BB bispecific antibody opatisumimab, LBL-024) for the treatment of metastatic colorectal cancer (mCRC). The approved clinical trial is an open-label, multicenter phase IB/II study to evaluate the safety and efficacy of Virixine™ in combination therapy for mCRC. This milestone marks an important step in expanding the indications of Villisin™ in gastrointestinal tumors. The company's immunotherapy landscape further extends from biliary tract cancer (BTC), gastric cancer (GC), and esophageal squamous cell carcinoma (ESCC) to colorectal cancer (CRC), a type of cancer with highly unmet clinical needs.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.